MedTrace Logo

Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

NCT01345539 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-11

Study results available
· View outcomes & findings →

Summary

This study will evaluate the feasibility of radiosurgery for all metastatic sites in patients presenting with oligometastatic disease, defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems.

Conditions

  • Oligometastatic Disease

Interventions

RADIATION

Stereotactic Radiosurgery (SRS)

Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.

DRUG

Chemotherapy

Chemotherapy choice of agents is at the discretion of the treating medical oncologist.

Sponsors & Collaborators

  • Steven Burton

    lead OTHER

Principal Investigators

  • Steve J Burton, MD · UPMC Hillman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-07
Primary Completion
2022-05-03
Completion
2022-10-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01345539 on ClinicalTrials.gov